Purpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials

Affiliations

¹ Shanthi Marur, Johns Hopkins University, Baltimore, MD; Anthony J. Cmelak, Vanderbilt-Ingram Cancer Center, Nashville, TN; and Barbara Burtness, Yale University School of Medicine, New Haven, CT.

Comment

Shanthi Marur et al. J Clin Oncol. 2017.

. 2017 Jun 10;35(17):1968-1969.

doi: 10.1200/JCO.2017.72.2918. Epub 2017 Apr 21.

¹ Shanthi Marur, Johns Hopkins University, Baltimore, MD; Anthony J. Cmelak, Vanderbilt-Ingram Cancer Center, Nashville, TN; and Barbara Burtness, Yale University School of Medicine, New Haven, CT.

No abstract available

Comment on

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. Marur S, et al. J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28. J Clin Oncol. 2017. PMID: 28029303 Free PMC article. Clinical Trial.
Is Induction Chemotherapy Needed to Select Patients for Deintensified Treatment of Human Papillomavirus-Associated Oropharyngeal Cancer?
Yom SS. Yom SS. J Clin Oncol. 2017 Feb 10;35(5):479-481. doi: 10.1200/JCO.2016.71.0681. Epub 2016 Dec 28. J Clin Oncol. 2017. PMID: 28029316 No abstract available.